Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|August 4, 2025
5 Pulmonology Headlines You Missed in July 2025
Author(s)Victoria Johnson
Fact checked by: Chelsie Derman
July 2025 saw a number of updates in COPD management and new research on RSV and COVID.
Advertisement
Advertisement
Amid continued advancements in pulmonary care, July 2025 delivered a mix of clinical insights, real-world perspectives, and evolving guidance that reflect the changing landscape of respiratory medicine. This month’s highlights span COPD management, viral respiratory illness, and post-COVID care—underscoring both emerging opportunities and persistent challenges in the field.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement